GlassScriptPhysician profile
William W Gladney
NPI 1801812748
$18,742.22
in general payments reported to CMS, 2019-2025
17 companies · $18.53 in 2025
The $18.53 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $82.05 · 2021: $10K · 2022: $5,811 · 2023: $1,253 · 2024: $674 · 2025: $18.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $787.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12,690.71 | 2021-2024 | |
| Amgen INC. | $4,089.98 | 2019-2022 | |
| Allergan, INC. | $824.81 | 2020-2021 | |
| Eisai INC. | $291.44 | 2023-2024 | |
| Lilly USA, LLC | $169.21 | 2024-2025 | Kisunla, Taltz, Amyvid |
| Novartis Pharmaceuticals Corporation | $134.63 | 2021 | |
| Sunovion Pharmaceuticals INC. | $124.25 | 2019 | |
| Biogen, INC. | $80.12 | 2022 | |
| Acadia Pharmaceuticals INC | $75.13 | 2019 | |
| Argenx US, INC. | $72.81 | 2024 | Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $44.22 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $40.38 | 2021-2024 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $39.86 | 2020-2021 | |
| Mdd US Operations, LLC | $19.79 | 2023 | Xadago, Apokyn |
| Lundbeck LLC | $18.31 | 2024 | Vyepti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $13.32 | 2022 | |
| Pfizer INC. | $13.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gladney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.